{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:28:22Z","timestamp":1790155702605,"version":"4.0.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,2,1]]},"DOI":"10.1093\/ndt\/gfi152","type":"journal-article","created":{"date-parts":[[2005,10,5]],"date-time":"2005-10-05T03:07:51Z","timestamp":1128481671000},"page":"345-354","source":"Crossref","is-referenced-by-count":219,"title":["Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting"],"prefix":"10.1093","volume":"21","author":[{"given":"Raphael","family":"Schiffmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Ries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Timmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roscoe O.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,10,4]]},"reference":[{"key":"key\n\t\t\t\t20171012184248_BIB1","doi-asserted-by":"crossref","unstructured":"Brady R, Gal AE, Bradley RM et al. Enzymatic defect in Fabry's disease. N Engl J Med1967; 276: 1163\u20131167","DOI":"10.1056\/NEJM196705252762101"},{"key":"key\n\t\t\t\t20171012184248_BIB2","doi-asserted-by":"crossref","unstructured":"Brady RO, Schiffmann R. Clinical features of and recent advances in therapy for Fabry disease. JAMA2000; 284: 2771\u20132775","DOI":"10.1001\/jama.284.21.2771"},{"key":"key\n\t\t\t\t20171012184248_BIB3","doi-asserted-by":"crossref","unstructured":"Ferrans VJ, Hibbs RG, Burda CD. The heart in Fabry's disease. A histochemical and electron microscopic study. Am J Cardiol1969; 24: 95\u2013110","DOI":"10.1016\/0002-9149(69)90055-1"},{"key":"key\n\t\t\t\t20171012184248_BIB4","unstructured":"Sessa A, Toson A, Nebuloni M et al. Renal ultrastructural findings in Anderson-Fabry disease. J Nephrol2002; 15: 109\u2013112"},{"key":"key\n\t\t\t\t20171012184248_BIB5","unstructured":"Sheth KJ, Werlin SL, Freeman ME et al. Gastrointestinal structure and function in Fabry's disease. Am J Gastroenterol1981; 76: 246\u2013251"},{"key":"key\n\t\t\t\t20171012184248_BIB6","doi-asserted-by":"crossref","unstructured":"Meikle PJ, Hopwood JJ, Clague AE et al. Prevalence of lysosomal storage disorders. JAMA1999; 281: 249\u2013254","DOI":"10.1001\/jama.281.3.249"},{"key":"key\n\t\t\t\t20171012184248_BIB7","doi-asserted-by":"crossref","unstructured":"Ries M, Gupta S, Moore DF et al. Pediatric Fabry disease. Pediatrics2005; 115: e344\u2013e355","DOI":"10.1542\/peds.2004-1678"},{"key":"key\n\t\t\t\t20171012184248_BIB8","doi-asserted-by":"crossref","unstructured":"Ries M, Ramaswami U, Parini R et al. The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr2003; 162: 767\u2013772","DOI":"10.1007\/s00431-003-1299-3"},{"key":"key\n\t\t\t\t20171012184248_BIB9","doi-asserted-by":"crossref","unstructured":"Whybra C, Kampmann C, Krummenauer F et al. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet2004; 65: 299\u2013307","DOI":"10.1111\/j.1399-0004.2004.00219.x"},{"key":"key\n\t\t\t\t20171012184248_BIB10","doi-asserted-by":"crossref","unstructured":"MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet2001; 38: 769\u2013775","DOI":"10.1136\/jmg.38.11.769"},{"key":"key\n\t\t\t\t20171012184248_BIB11","doi-asserted-by":"crossref","unstructured":"Baehner F, Kampmann C, Whybra C et al. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J Inherit Metab Dis2003; 26: 617\u2013627","DOI":"10.1023\/B:BOLI.0000005658.14563.77"},{"key":"key\n\t\t\t\t20171012184248_BIB12","doi-asserted-by":"crossref","unstructured":"Schiffmann R, Floeter MK, Dambrosia JM et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve2003; 28: 703\u2013710","DOI":"10.1002\/mus.10497"},{"key":"key\n\t\t\t\t20171012184248_BIB13","doi-asserted-by":"crossref","unstructured":"Cable WJ, Kolodny EH, Adams RD. Fabry disease: impaired autonomic function. Neurology1982; 32: 498\u2013502","DOI":"10.1212\/WNL.32.5.498"},{"key":"key\n\t\t\t\t20171012184248_BIB14","doi-asserted-by":"crossref","unstructured":"Branton MH, Schiffmann R, Sabnis SG et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore)2002; 81: 122\u2013138","DOI":"10.1097\/00005792-200203000-00003"},{"key":"key\n\t\t\t\t20171012184248_BIB15","doi-asserted-by":"crossref","unstructured":"Perrot A, Osterziel KJ, Beck M et al. Fabry disease: focus on cardiac manifestations and molecular mechanisms. Herz2002; 27: 699\u2013702","DOI":"10.1007\/s00059-002-2429-9"},{"key":"key\n\t\t\t\t20171012184248_BIB16","doi-asserted-by":"crossref","unstructured":"Kampmann C, Wiethoff CM, Martin C et al. Electrocardiographic signs of hypertrophy in Fabry disease-associated hypertrophic cardiomyopathy. Acta Paediatr Suppl2002; 91: 21\u201327","DOI":"10.1111\/j.1651-2227.2002.tb03105.x"},{"key":"key\n\t\t\t\t20171012184248_BIB17","doi-asserted-by":"crossref","unstructured":"Moore DF, Altarescu G, Ling GS et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke2002; 33: 525\u2013531","DOI":"10.1161\/hs0202.102601"},{"key":"key\n\t\t\t\t20171012184248_BIB18","doi-asserted-by":"crossref","unstructured":"Moore DF, Altarescu G, Herscovitch P et al. Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. BMC Neurol2002; 2: 4","DOI":"10.1186\/1471-2377-2-4"},{"key":"key\n\t\t\t\t20171012184248_BIB19","doi-asserted-by":"crossref","unstructured":"Moore DF, Scott LT, Gladwin MT et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation2001; 104: 1506\u20131512","DOI":"10.1161\/hc3801.096352"},{"key":"key\n\t\t\t\t20171012184248_BIB20","doi-asserted-by":"crossref","unstructured":"MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet2001; 38: 750\u2013760","DOI":"10.1136\/jmg.38.11.750"},{"key":"key\n\t\t\t\t20171012184248_BIB21","doi-asserted-by":"crossref","unstructured":"Ojo A, Meier-Kriesche HU, Friedman G et al. Excellent outcome of renal transplantation in patients with Fabry's disease. Transplantation2000; 69: 2337\u20132339","DOI":"10.1097\/00007890-200006150-00020"},{"key":"key\n\t\t\t\t20171012184248_BIB22","doi-asserted-by":"crossref","unstructured":"Thadhani R, Wolf M, West ML et al. Patients with Fabry disease on dialysis in the United States. Kidney Int2002; 61: 249\u2013255","DOI":"10.1046\/j.1523-1755.2002.00097.x"},{"key":"key\n\t\t\t\t20171012184248_BIB23","doi-asserted-by":"crossref","unstructured":"Tsakiris D, Simpson HK, Jones EH et al. Report on management of renal failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrol Dial Transplant1996; 11: 4\u201320","DOI":"10.1093\/ndt\/11.supp7.4"},{"key":"key\n\t\t\t\t20171012184248_BIB24","doi-asserted-by":"crossref","unstructured":"Schiffmann R, Kopp JB, Austin HA, 3rd et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA2001; 285: 2743\u20132749","DOI":"10.1001\/jama.285.21.2743"},{"key":"key\n\t\t\t\t20171012184248_BIB25","doi-asserted-by":"crossref","unstructured":"Eng CM, Guffon N, Wilcox WR et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med2001; 345: 9\u201316","DOI":"10.1056\/NEJM200107053450102"},{"key":"key\n\t\t\t\t20171012184248_BIB26","doi-asserted-by":"crossref","unstructured":"Levey AS. Clinical practice: Nondiabetic kidney disease. N Engl J Med2002; 347: 1505\u20131511","DOI":"10.1056\/NEJMcp013462"},{"key":"key\n\t\t\t\t20171012184248_BIB27","unstructured":"K\/DOQI NKF. Kidney Disease Outcome Quality Initiative. Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis2002; 39 [2 suppl 2]: S1\u2013S246"},{"key":"key\n\t\t\t\t20171012184248_BIB28","doi-asserted-by":"crossref","unstructured":"Rosenberg M, Kingma W, Fitzpatrick MA et al. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood1999; 93: 2081\u20132088","DOI":"10.1182\/blood.V93.6.2081.406k07_2081_2088"},{"key":"key\n\t\t\t\t20171012184248_BIB29","doi-asserted-by":"crossref","unstructured":"Beck M, Ricci R, Widmer U et al. Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest2004; 34: 838\u2013844","DOI":"10.1111\/j.1365-2362.2004.01424.x"},{"key":"key\n\t\t\t\t20171012184248_BIB30","doi-asserted-by":"crossref","unstructured":"Gadoth N, Sandbank U. Involvement of dorsal root ganglia in Fabry's disease. J Med Genet1983; 20: 309\u2013312","DOI":"10.1136\/jmg.20.4.309"},{"key":"key\n\t\t\t\t20171012184248_BIB31","unstructured":"Kampmann C, Whybra C, Baehner FA, Beck M. Enzyme replacement in Anderson-Fabry Cardiomyopathy Heart Metab2002; 39\u201341"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/21\/2\/345\/5234844\/gfi152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T02:05:17Z","timestamp":1586484317000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ndt\/article\/21\/2\/345\/1850640\/Longterm-therapy-with-agalsidase-alfa-for-Fabry"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,4]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2005,10,4]]},"published-print":{"date-parts":[[2006,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfi152","relation":{},"ISSN":["1460-2385","0931-0509"],"issn-type":[{"value":"1460-2385","type":"electronic"},{"value":"0931-0509","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,2]]},"published":{"date-parts":[[2005,10,4]]}}}